For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Napro Biotherapeutics, Inc.

USPTO Granted Patents = 33

% Expired Patents = 21.2

Forward Citations = 382

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

James D McChesney (12 out of 58 patents)

Nicholas J Sisti (12 out of 14 patents)

Madhavi C Chander (11 out of 13 patents)

4. David Reginald Carver (10 out of 47 patents)

5. Timothy R Prout (10 out of 10 patents)

6. Jan J Zygmunt (9 out of 30 patents)

7. Charles S Swindell (8 out of 27 patents)

8. Hernita A Ewald (8 out of 8 patents)

9. Robyn Elliott (6 out of 6 patents)

10. Paul Handreck (6 out of 6 patents)

11. Herbert R Brinkman (5 out of 5 patents)

12. Xian Liang (4 out of 7 patents)

13. Donia L Henderson (3 out of 3 patents)

14. Christopher T Workman (2 out of 7 patents)

15. Charles L Hughes (2 out of 2 patents)

Core Competencies:

Taxanes

Paclitaxel

10-DAB III

Hydrazinolysis

Chiral Resolution

Baccatin III

Docetaxel

Isotope Labeling

Therapeutic Regimen

Acylation

Pharmaceutical Composition

Tumor Cell Sensitivity

33 patents: Sort by Forward Citations

1. 6770670 - Injectable composition (2004-08-03),

2. 6653501 - Chiral resolution method for producing compounds useful in the synthesis of taxanes (2003-11-25),

3. 6509484 - Synthesis of taxol, taxol analogs and their intermediates with variable a-ring side chain structures and compositions thereof (2003-01-21),

4. 6495705 - Efficient process for the production of 10-DAB III by selective hydrazinolysis of various taxanes (2002-12-17),

5. 6479679 - Two-step conversion of protected taxane ester to paclitaxel (2002-11-12),

6. 6452025 - Three-step conversion of protected taxane ester to paclitaxel (2002-09-17),

7. 6448417 - Methods and useful intermediates for paclitaxel synthesis from C-7, C-10 di-cbz 10-deacetylbaccatin III (2002-09-10),

8. 6358996 - Stable isotope labeling of paclitaxel (2002-03-19),

9. 6306894 - Injectable composition (2001-10-23),

10. 6281368 - Simple and efficient hydrazinolysis of C-10 and C-13 ester functionalities of taxanes to obtain 10-DAB III (2001-08-28),

11. 6143902 - C-2 hydroxyl protected-N-acyl (2R,3S)-3-phenylisoserine N-imido (2000-11-07),

12. 6140359 - Injectable composition (2000-10-31),

13. 6136999 - C-2 hydroxyl protected-n-acyl (2R,3S)-3-phenylisoserine substituted (2000-10-24),

14. 6133462 - C-7 CBZ baccatin III and production method therefor (2000-10-17),

15. 6107497 - Intermediate for use in docetaxel synthesis and production method (2000-08-22),

Company Overview

Napro Biotherapeutics, Inc. is a biotechnology company based in Boulder, Colorado, focused on developing innovative therapeutic solutions. The organization specializes in the research and development of biopharmaceuticals, particularly in the areas of drug delivery systems and targeted therapies. By leveraging advanced technologies, Napro aims to enhance treatment efficacy and patient outcomes across various medical conditions, positioning itself as a key player in the biotherapeutics landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

33 Patents

#45 in Boulder, CO

#211 in Colorado

#10,309 in US

#20,162 in the World

Boulder, CO, United States of America

Napro Biotherapeutics, Inc.

Forward Citations = 382

23 inventors:

James D McChesney (12 out of 58 patents)

Nicholas J Sisti (12 out of 14 patents)

Madhavi C Chander (11 out of 13 patents)

4. David Reginald Carver (10 out of 47 patents)

5. Timothy R Prout (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Napro Biotherapeutics, Inc.. Retrieved from https://idiyas.com/company/napro-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…